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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized
by the progressive loss of motor neurons. The cause of this selective neuronal death is
unknown, but transcriptional dysregulation is recently emerging as an important factor.
The physical substrate for the regulation of the transcriptional process is chromatin, a
complex assembly of histones and DNA. Histones are subject to several post-translational
modifications, like acetylation, that are a component of the transcriptional regulation
process. Histone acetylation and deacetylation is performed by a group of enzymes
(histone acetyltransferases (HATs) and deacetylases, respectively) whose modulation
can alter the transcriptional state of many regions of the genome, and thus may be
an important target in diseases that share this pathogenic process, as is the case for
ALS. This review will discuss the present evidence of transcriptional dysregulation in
ALS, the role of histone deacetylases (HDACs) in disease pathogenesis, and the novel
pharmacologic strategies that are being comprehensively studied to prevent motor neuron
death, with focus on sirtuins (SIRT) and their effectors.
Keywords: amyotrophic lateral sclerosis, neurodegeneration, neuroprotection, transcription dysregulation,
histone deacetylases, sirtuins
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease characterized by the death of upper and lower motor
neurons. There are two type of ALS based on the presence of
an identified mutation as a cause of the disease. The familial
type (fALS) is most commonly caused by mutations in the
superoxide dismutase type 1 (SOD1) gene, for which there is
a widely studied transgenic mouse model; however fALS rep-
resents only about 10% of cases. The most common type of
ALS is called sporadic (sALS), but because there are no iden-
tified etiologic factors, validated experimental models lack for
this type of the disease. Nevertheless, disease progression and
pathologic characteristics in both, fALS and sALS, are similar.
Also, in both types of the disease, motor neuron degenera-
tion has been associated with the same mechanisms, such as
glutamate-mediated excitotoxicity, inflammatory events, axonal
transport deficits, oxidative stress and mitochondrial dysfunction
(for recent reviews see Corona et al., 2007; Santa-Cruz et al.,
2012).
Besides these factors, a novel mechanism that may be involved
in motor neuron death and other neurodegenerative diseases is
transcriptional dysfunction, which consists of aberrations of the
molecular machinery that regulates gene expression, especially
at the transcriptional levels through the manipulation of epige-
netic marks (Robberecht and Philips, 2013). These marks are
covalent modifications of the chromatin components, DNA and
histone proteins, carried out by several key enzymes that finely
modulate the status of these marks. Among these marks, histone
acetylation has been characterized as an important mechanism
in the regulation of the opening of chromatin configuration
leading to increased transcription (Kouzarides, 2007). The status
of histone acetylation strongly depends on the activity of histone
deacetylases (HDACs), a widely conserved family of enzymes that
catalyze the removal of acetyl groups from histones and from
other proteins. This family, which includes sirtuins (SIRT), has
been shown to be important for several cellular processes, such
as cell death and stress responses, which makes them attractive
for the study of their pathogenic role and as potential therapeutic
targets (Haigis and Sinclair, 2010).
This paper will review, first the evidence of transcriptional
dysregulation in ALS, then the role of the different members
of the HDACs family in disease pathogeny and as therapeutic
candidates, and finally the role of SIRT and their effectors in ALS.
RELEVANCE OF HISTONE ACETYLATION IN GENE
EXPRESSION
Protein acetylation is an important postranslational modification
that regulates numerous cellular functions, such as microtubule
dynamics and intracellular transport (Hubbert et al., 2002), devel-
opment (Bhaumik et al., 2007), metabolism (Cantó et al., 2009),
and transcriptional regulation through chromatin remodeling
(Kouzarides, 2007).
In eukaryotic cells, including neurons, the genome is orga-
nized through the association of DNA with protein complexes,
an assembly called chromatin. The most abundant proteins are
histones, and these proteins assemble themselves into octamers,
composed of two copies of the histones types H2A, H2B, H3
and H4. Around the octamer, ∼147 bp of DNA is wrapped,
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forming the basic unit of chromatin, the nucleosome. Nucleo-
somes further organize themselves in increasingly complex struc-
tures, all of which are subject to modulation, by changing the
accessibility of the regulatory regions of DNA (such as pro-
moters, enhancers, silencers or insulators) to the transcriptional
machinery, ultimately affecting gene expression (Zhou et al.,
2011). This regulation can be accomplished through covalent
modifications of the chromatin components: in the DNA it occurs
through cytosine methylation and hydroxymethylation, and in
the histones through methylation, ubiquitinylation, sumoylation,
phosphorylation and acetylation of selected aminoacid residues
(Kouzarides, 2007). In general terms, gene expression is directly
proportional the level of histone acetylation; because of this,
the regulation of this postranslational modification is essential
for gene homeostasis. Such regulation depends on two groups
of enzymes: histone acetyltransferases (HATs) and HDACs, and
drastic alterations to this control of gene expression can be delete-
rious, as has been proven in various tumor cell models (Frew et al.,
2009). Therefore, the upregulation of the expression of a given
gene can be accomplished by stimulating the activity of HATs or
by inhibiting the activity of HDACs (Kazantsev and Thompson,
2008). Currently, research on HATs and on their possible pro-
tective effects on neurodegenerative processes is scarce and no
specific activators are known, whereas information onHDACs has
become the subject of many studies (Selvi et al., 2010). Although
histones are not the only target of these enzymes, and in some
instances they are not a target at all, the name HDACs is preserved
for historical reasons. They constitute a family integrated in a
complex network of intracellular signaling participating through
acetylation/deacetylation reactions, with numerous protein sub-
strates and multiple physiological consequences depending on
the protein involved (de Ruijter et al., 2003; Kazantsev and
Thompson, 2008).
EVIDENCE OF TRANSCRIPTIONAL DYSREGULATION IN ALS
There is evidence that transcriptional dysregulation could con-
tribute to, and possibly be the cause of, some neurodegenerative
disorders. This was first proposed for Huntington’s disease (Cha,
2000) and relevant findings have been encountered in exper-
imental in vitro and in vivo models of Alzheimer’s (Robakis,
2003) and Parkinson’s diseases (Yacoubian et al., 2008). In the
case of ALS, there is also evidence of transcriptional dysregula-
tion and alterations in the transcriptome in both the sporadic
(Figueroa-Romero et al., 2012) and the familial (Kirby et al.,
2005) types of the disease. Although the mechanisms and causal
relationships have yet to be elucidated, it has been proposed that
neuronal protein inclusions, such as those formed by mutated
SOD1 or TDP43 (43-kDa transactivator response region (TAR)
DNA-binding domain protein) which have been found in ALS
and in frontotemporal dementia, could cause their toxicity by
acting as surface attractants that sequester vital components of
the transcriptional machinery, as was first proved for huntingtin
(Cha, 2000). For example, in a screening study to identify targets
that disrupt SOD1 aggresome in cultured cells, HDAC inhibition
was shown to prevent aggresome formation (Corcoran et al.,
2004).
Transcription might also be altered indirectly by modifi-
cations of other regulatory components of the transcriptional
process, such as HDAC activity. For example, in a Drosophila
model of polyglutamine neurodegeneration, it was shown that
the upregulation of HDACs can ameliorate neuronal death due
to a selective transcriptional repression of the CGG repeat-
containing gene (Todd et al., 2010). Also, HDAC inhibition
is protective for cultured motor neurons against excitotoxicity,
a mechanism known to be involved in ALS pathophysiology,
due to their ability to modulate gene expression (Kanai et al.,
2004). Hence, although the role of transcriptional dysfunction in
neurodegenerative diseases is still under study, there is increas-
ing evidence for a role of HDACs in the neurodegenerative
processes through the modulation of transcriptional machin-
ery.
HISTONE DEACETYLASES: ROLE OF CLASSES I AND II IN
MOTOR NEURON DEGENERATION
Based on structural, localization and functional criteria, HDAC
superfamily is composed of five classes. First, in the next para-
graphs, we will focus on the “typical” HDACs (11 enzymes,
classified in classes I, IIa, IIb and IV), their distribution and the
evidence of their role in ALS. The role of SIRT (seven enzymes
that constitute class III or “atypical” HDACs) will be addressed
later.
Class I and II HDACs are Zn2+-dependent enzymes. Class
I include HDAC1, HDAC2, HDAC3 and HDAC8, which are
localized in the nucleus and ubiquitously expressed in mam-
malian tissues (except HDAC8, which is muscle-specific). Broadly
speaking, these enzymes are involved in the regulation of gene-
specific transcription through the formation of stable transcrip-
tional complexes (de Ruijter et al., 2003). Of these, HDAC2 and
HDAC3 seem to have a more important role in the physiology
of the central nervous system. Broide et al. (2007) described the
distribution of 11 HDACs mRNAs in 50 screened areas of the rat
brain, using high-resolution in situ hybridization; HDAC2 and
HDAC3 were widely expressed in all areas, especially those of
the limbic system (amygdala, piriform cortex, olfactory bulb and
hippocampus) and in the granule cell layer of cerebellum, and at
the cellular level were found in neurons and oligodendrocytes. In
a recent report, a similar distribution of HDAC2 was found in
the mouse brain, as well as a moderate expression in primary
and secondary motor cortices, and Rexed’s laminae 4–9 of the
cervical spinal cord (where motor neurons reside). Again, HDAC2
was noted only in neurons and oligodendrocytes, within the
nucleus (Yao et al., 2013). Due to their ubiquitous expression in
brain and spinal cord, these HDACs have also been implicated
in ALS. Janssen et al. (2010) found in ALS patients that HDAC2
expressionwas upregulated inmotor cortex (in layers III–V,where
upper motor neuron are located) and in spinal cord grey matter,
particularly in the nuclei of motor neurons; they interpreted
this result as a protective role of HDAC2 in ALS pathogenesis,
although the mechanisms of this effect were not detailed. Regard-
ing this issue, in an in vitro study Kernochan et al. (2005) reported
that HDAC inhibition increased promoter activity of the survival
motor neuron 2 gene, and this was associated with HDAC2
levels.
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Class IIa –HDACs 4, 5, 7 and 9– shuffle between the nucleus
and the cytoplasm, and their substrates have not been defined;
they have histone deacetylase activity only by interacting with
HDAC3 (de Ruijter et al., 2003). HDAC4 and 5 expressions were
high in all screened areas, and their locations mimic that of class I
HDACs (Broide et al., 2007).
Class IIb is composed of HDAC6 and HDAC10. Again,
HDAC10 substrates have not been defined, but it is known that
it associates with HDAC3 (de Ruijter et al., 2003). HDAC6 is an
unusual enzyme, in the sense that it has two catalytic domains
and functions in the cytoplasm where it deacetylates α-tubulin
and alters microtubule stability (Hubbert et al., 2002). Further-
more, inhibition of this enzyme stimulates autophagy and the
proteasome system in a Drosophila model of spinal muscular
atrophy (a neurodegenerative disease of spinal motor neurons)
resulting in increased survival (Pandey et al., 2007). In the rat
brain, its expression is low (Broide et al., 2007) and no changes
were noted in ALS patients (Janssen et al., 2010). Nevertheless,
evidence of the role of HDAC6 in ALS is emerging. In a recent
work it was found that TDP43 and fused in sarcoma/translated
in liposarcoma (FUS/TLS), which are proteins that regulate RNA
processing and have been found to be mutated in some cases
of ALS, interact with each other forming a ribonucleoprotein
complex that regulates the expression of HDAC6 through its
mRNA stability (Kim et al., 2010).
Class IV HDAC only member, HDAC11, is localized in the
cell nucleus and is structurally different from the other classes
(Kazantsev and Thompson, 2008). Although its functions are
poorly understood, recent reports indicate that this HDAC is
abundantly and almost exclusively expressed in the mammalian
nervous system, within oligodendrocytes (Liu et al., 2008), and
also plays an important role in thematuration of this cell type (Liu
et al., 2009b). In other study in the rat brain, HDAC11 expression
was found to be ubiquitously distributed, in both neurons and
oligodendrocytes; in fact, this HDAC displayed the highest levels
of expression of all HDACs (Broide et al., 2007). In nervous tissue
of ALS patients, including the ventral horn of the spinal cord, the
nucleus and the cytoplasm of motor neurons showed decreased
HDAC11 mRNA levels (Janssen et al., 2010).
PROTECTIVE EFFECTS OF HDAC INHIBITION
Chen et al. (2012) addressed the role of class I and II HDACs
in an experimental model of acute stroke in rodents. There was
progressive decline of mRNA levels of HDACs 1, 2, 5 and 9 in
cerebral cortex, while HDACs 3, 6 and 11 mRNA levels were
transiently increased. In addition, in an in vitro model of glucose-
oxygen deprivation, they reported that selective inhibition of
HDAC3 and HDAC6 promoted neuronal survival.
Currently there is an ample battery of small-molecule HDACs
inhibitors, that were initially developed to halt cell proliferation
in cancer experimental models; HDACs inhibitors are classified
as hydroxamate-based (vorinostat, valproic acid (VPA), sodium
butyrate, trichostatin A, 4-phenyl butyrate, MC1568 –class II
selective–, and tubucin –HDAC6 specific–), and benzamide-based
(MS275, compound 106). Their potencies and selectivities vary,
but most of them can be considered pan-HDACs inhibitors
(Kazantsev and Thompson, 2008).
Several of these compounds have been studied in the trans-
genic SOD1 mouse model. Trichostatin A induced a modest
improvement in motor function and survival as well as protection
against motor neuron death, axonal degeneration, muscle atro-
phy and neuromuscular junction denervation; these effects were
attributed to reduced gliosis and upregulation of the glutamate
transporter (GLT-1) in the spinal cord (Yoo and Ko, 2011).
VPA is a drug currently in clinical use for other neurological
disorders (such as epilepsy and bipolar disorder) due to its numer-
ous mechanisms of action, including HDAC inhibition (Monti
et al., 2009). VPA was tested in vivo in the transgenic ALS SOD1
mice, where it did not improve survival or motor performance,
but it did improve the acetylation status in the spinal cord through
the restoration of the cAMP response element binding protein
(CREB) levels in motor neurons and slightly prevented motor
neurondeath (Rouaux et al., 2007). VPAhas already been tested in
ALS patients in one clinical trial, showing no benefits in survival
or in disease progression in doses commonly used to treat epilepsy
(Piepers et al., 2009).
Sodium phenylbutyrate (SPB), another pan-HDAC inhibitor,
was shown to extend survival and motor performance in the
transgenic ALS SOD1 animal model, and these effects were
attributed to an upregulation in the expression of nuclear factor
κB (NF-κB), the active form of the inhibitory subunit of NF-κB
(i-κB) and of beta cell lymphoma 2 (bcl-2) proteins, all involved
in survival and stress responses (Ryu et al., 2005). SPB efficacy
has been tested also in combinations with other agents with
different mechanisms of action, in the same experimental model.
For example, the combination of SPB with riluzole potentiated
the beneficial effects of SPB on survival and motor performance,
although the authors did not address the possible mechanisms
(Del Signore et al., 2009). SPB has also been tested in combination
with an antioxidant agent (AEOL 10150), where it was found that
this combination extended survival more than either treatment
alone (Petri et al., 2006). Finally, it is worth to emphasize that
SPB has already been tested in a phase 2 clinical trial, where
its effects on histone acetylation status, safety and tolerability
were addressed; no toxic effects were noted, and significant
increases were observed in the blood histone acetylation status,
but the therapeutic efficacy of such treatment was not studied
(Cudkowicz et al., 2009).
HISTONE DEACETYLASES: ROLE OF SIRTUINS IN MOTOR
NEURON DEGENERATION
Class III HDACs, also called SIRT, are the most divergent class
from the rest of the family. This class includes seven members
(SIRT1 to SIRT7) with various cellular localizations and pre-
ferred enzymatic targets, but what makes unique this class is the
dependence of nicotine adenine dinucleotide (NAD+) to perform
their catalytic deacetylation and mono-ADP-ribosyl transferase
activities (Michan and Sinclair, 2007). SIRT1, SIRT2, SIRT3 and
SIRT5 have predominant histone deacetylase activity (Haigis
and Sinclair, 2010). SIRT1, SIRT6 and SIRT7 are located in the
nucleus. SIRT1 has a preference for euchromatin and can be
shuttled to the cytoplasm, depending on the cell type and the
developmental stage (Tanno et al., 2007). SIRT6 tends to associate
with heterochromatin and SIRT7 is located in the nucleolus.
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SIRT2 resides mostly in the cytoplasm, having an important role
in regulation cytoskeletal dynamics. SIRT3, SIRT4 and SIRT5 are
mitochondrial (Michan and Sinclair, 2007).
SIRT are named after the silent information regulator 2 (sir2)
gene in yeast. When overexpressed, the product of this gene
extended the lifespan of budding yeast by repressing genomic
instability (Kaeberlein et al., 1999). After that discovery, it was
learned that SIR2-like genes or SIRT are found inmost organisms,
where they regulate basic vital functions. In mammals, sirtuin
activation or overexpression do not extend lifespan, but appear
to be involved in the benefits of calorie restriction, are responsive
to environmental stimuli (e.g., daylight and cell stress), and play
important roles in numerous human diseases, such as cancer,
diabetes, cardiovascular disease and neurodegeneration (Haigis
and Sinclair, 2010).
The catalytic deacetylase activity of SIRT is performed on
histones and on other proteins, and this ability place SIRT in a
privileged position to exert their actions on the genome through
direct and indirect pathways. Among the non-histone protein
substrates, the peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (PGC1-α; Cantó and Auwerx, 2009) and the
forkhead box O3a (FoxO3a) transcription factor (Zhao et al.,
2011b) are two of the most studied, and their relation to ALS will
be discussed below. Also, SIRT play an important role as cellular
energy sensors (Smith et al., 2000), due to their dependence on
NAD+ as a substrate (Imai et al., 2000); in humans, SIRT1-
3 and 5 have shown in vitro NAD+-dependent deacetylating
activity (Smith et al., 2000). Therefore, SIRT provide a connection
between cellular energy states and transcriptional control (Li,
2013).
SIRT have a widespread distribution in themammalian tissues,
including the nervous system. In the mouse, rat and human
CNS, SIRT1 mRNA localization was found to be ubiquitous and
prominent in various tissues (such as all regions of spinal cord,
hippocampus, basal ganglia, brain stem and cerebellum); SIRT1
expression is confined to the neuronal nucleus in parvalbumin
(GABAergic) and tyrosine hydroxylase (dopaminergic) neurons
(Zakhary et al., 2010). SIRT1 expression was increased in cerebral
cortex (especially in the pyramidal cell layer), hippocampus,
thalamus and spinal cord in symptomatic SOD1 G93A mice, but
spinal motor neurons were not studied in detail; these changes
were interpreted as a stress response to the neurotoxic form of
SOD1 (Lee et al., 2012).
PROTECTIVE EFFECTS OF SIRTUINS ACTIVATION
In contrast to other HDACs, the activity of SIRT in the CNS
results in neuroprotection. Among the agents with protective
action are the polyphenols (vegetal compounds that serve hor-
monal and protective function in these organisms), particularly
resveratrol, which is present in grapes and in red wine, and
SRT1720, a synthetic compound derived from resveratrol. These
compounds activate selectively both SIRT1 and SIRT2, whereas
activators of the remaining SIRT have not yet been described
(Kazantsev and Thompson, 2008).
There is a paucity of studies that address SIRT role in ALS
pathology. In primary cortical cultures of transgenic SOD1 G93A
mice, resveratrol protected against neuron death, and this pro-
tection was due to the activation of SIRT1 (Kim et al., 2007).
In agreement with these results, in another in vitro study of
SOD1 G93A murine motor neurons, it was found that SIRT1
expression was downregulated, and resveratrol prevented neu-
ronal death (Wang et al., 2011). However, the neuroprotection
exerted by resveratrol may be due to the stimulation of the
activities of other enzymes such as AMP protein kinase (Dasgupta
and Milbrandt, 2007). In our laboratory we have recently found
that the administration of resveratrol directly in the lum-
bar spinal cord in rats delays the progress of motor deficits
induced by chronic AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazol-propionate) infusion in the lumbar spinal cord (Lazo-
Gómez and Tapia, in preparation, an in vivo model of excitotoxic
motor neuron death (Tovar-y-Romo et al., 2007).
The downstream effectors of SIRT that confer protection in
neurodegenerative settings are beginning to be elucidated. For
example, in a transgenic mouse model of Huntington’s disease,
SIRT1 overexpression exerted its beneficial effects through the
deacetylation of FoxO3a and p53 (Jiang et al., 2012). This relation
has not been explicitly addressed in ALS experimental models, but
there is evidence of the role of SIRT1 effectors in motor neuron
death. FoxO3a is a transcriptional factor involved in determining
cell fate (survival or apoptosis) in stressful situations, such as star-
vation and oxidative stress. It has been shown that SIRT1 modu-
lates FoxO3a activities through the deacetylation of specific lysine
residues, resulting in activation or inhibition, and this depends
on the deacetylated lysine position or on FoxO3a cellular location
(nucleus or cytoplasm) (Eijkelenboom and Burgering, 2013). In
an in vitro study of motor neuron death induced by several
insults (excitotoxicity, the overexpression of mutant SOD1, of
mutant p150glued or of poly-glutamin expanded androgen recep-
tor), targeted expression of FoxO3a to the nucleus (where it
can modulate the transcription of its target genes) by genetic
or pharmacologic means prevented neuron death (Mojsilovic-
Petrovic et al., 2009). This is in contrast with other in vitro studies,
where motor neuron cultures deprived of trophic support were
found to overexpress Fas ligand (FasL), due to FoxO3a translo-
cation to the nucleus, thus resulting in cell death (Barthélémy
et al., 2004). The reason for this discrepancy is not clear, but it
could be due to differences in the death process triggered by the
various insults used, which might be regulated in different ways by
FoxO3a.
Another well studied SIRT1 effector is PGC1-α, a transcrip-
tional coactivator involved in the modulation of the responses
necessary to overcome cellular energetic deficiencies, such as the
stimulation of mitochondrial biogenesis and the respiratory rate,
and the increase of the uptake and metabolism of energy sub-
strates. SIRT1 physically interacts with, deacetylates and activates
PGC1-α (Cantó and Auwerx, 2009). It has been shown that
PGC1-α plays a role in ALS pathology, because decreased mRNA
and protein levels of this coactivator were found in both trans-
genic mice and in patients with the sporadic form of the disease,
in muscle and in spinal cord tissues (Thau et al., 2012). Moreover,
PGC1-α may play a therapeutic role, as shown by two studies in
the transgenic mouse model. Zhao et al. (2011a) used a targeted
overexpression of PGC1-α in neurons of SOD1 transgenic mice,
which modestly increased survival and significantly improved
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motor performance; these changes were due to the restoration
of mitochondrial activities. This is in contrast to the findings of
other study in a double transgenic mouse overexpressing PGC1-α
and mutant SOD1 in all tissues, showing that survival was not
increased albeit motor performance improved and motor neuron
loss was ameliorated. An augmentation of the excitatory amino
acid transporter protein 2 (EAAT2) in astrocytes was noted in
the double transgenic, suggesting that PGC1-α could exert its
beneficial effects through other mechanisms (Liang et al., 2011).
Regarding other sirtuin isoforms, such as SIRT3, a mitochondrial
sirtuin, Song et al. (2013) showed, in primary spinal motor
neuronal cell cultures of transgenic SOD1 G93A mice, that the
overexpression of SIRT3 and of PGC1-α protected against mito-
chondrial fragmentation and neuronal cell death, although the
authors did not demonstrate the relation between SIRT3 and
PGC1-α.
These findings indicate that sirtuin activation protects against
motor neuron degeneration, although some findings in different
experimental models suggest that activators may protect through
other mechanisms (Tang, 2010) or even that sirtuin inhibition
may be protective. For example, in a model of brain ischemia
sirtuin inhibition through nicotinamide administration conferred
neuroprotection by preserving NAD+ cellular levels (Liu et al.,
2009a).
CONCLUSION
The opportunities for a really effective therapy for ALS are
scarce, and therefore HDAC inhibition and sirtuin activation
merit further investigation. Studies on the modification of the
activity of these enzymes in in vitro and in vivo experimental
models of neurodegeneration, including ALS, have given valuable
information suggesting potential therapeutic opportunities for
this disease. Nevertheless, the mechanisms underlying such effects
are poorly understood and their clarification is necessary for
designing more specific and potent treatment strategies. Accu-
mulated evidence on sirtuin activation has provided valuable
information about the molecular pathways that could be relevant
to halt motor neuron degeneration, such as those related to
cellular energetic state and PGC1-α. Not all types of HDACs
have been evaluated in ALS models and the effects, toxicity,
dosage, timing, and mode of administration of specific drugs
that inhibit HDAC or activate SIRT have not been established.
Of note is the fact that the most widely used model of ALS in
which these strategies have been studied is the transgenic rodent
with mutations in the human SOD1 gene, but this represent
only about 2% of all ALS cases. Novel experimental models of
motor neuron degeneration in vivo are clearly needed before
safely moving these drugs to clinical trials for a disorder that
has proved recalcitrant to all, past and current, therapeutic
procedures.
ACKNOWLEDGMENTS
This work was supported by Dirección General de Asuntos del
Personal Académico, UNAM (project IN201013) and Consejo
Nacional de Ciencia y Tecnología (CONACYT), México (project
128229). Rafael Lazo-Gómez and Uri N. Ramírez-Jarquín are
recipients of a CONACyT scholarship.
REFERENCES
Barthélémy, C., Henderson, C. E., and Pettmann, B. (2004). Foxo3a induces
motoneuron death through the Fas pathway in cooperation with JNK. BMC
Neurosci. 5:48. doi: 10.1186/1471-2202-5-48
Bhaumik, S. R., Smith, E., and Shilatifard, A. (2007). Covalent modifications of
histones during development and disease pathogenesis. Nat. Struct. Mol. Biol.
14, 1008–1016. doi: 10.1038/nsmb1337
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., and Winrow,
C. J. (2007). Distribution of histone deacetylases 1–11 in the rat brain. J. Mol.
Neurosci. 31, 47–58. doi: 10.1007/bf02686117
Cantó, C., and Auwerx, J. (2009). PGC-1alpha, SIRT1 and AMPK, an energy
sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20, 98–
105. doi: 10.1097/mol.0b013e328328d0a4
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne,
J. C., et al. (2009). AMPK regulates energy expenditure by modulating
NAD+ metabolism and SIRT1 activity. Nature 458, 1056–1060. doi: 10.
1038/nature07813
Cha, J. H. (2000). Transcriptional dysregulation in Huntington’s disease. Trends
Neurosci. 23, 387–392. doi: 10.1016/s0166-2236(00)01609-x
Chen, Y. T., Zang, X. F., Pan, J., Zhu, X. L., Chen, F., Chen, Z. B., et al. (2012).
Expression patterns of histone deacetylases in experimental stroke and potential
targets for neuroprotection. Clin. Exp. Pharmacol. Physiol. 39, 751–758. doi: 10.
1111/j.1440-1681.2012.05729.x
Corcoran, L. J., Mitchison, T. J., and Liu, Q. (2004). A novel action of histone
deacetylase inhibitors in a protein aggresome disease model. Curr. Biol. 14, 488–
492. doi: 10.1016/j.cub.2004.03.003
Corona, J. C., Tovar-y-Romo, L. B., and Tapia, R. (2007). Glutamate excitotoxicity
and therapeutic targets for amyotrophic lateral sclerosis. Expert Opin. Ther.
Targets 11, 1415–14128. doi: 10.1517/14728222.11.11.1415
Cudkowicz, M. E., Andres, P. L., Macdonald, S. A., Bedlack, R. S., Choudry,
R., Brown, R. H., et al. (2009). Phase 2 study of sodium phenylbutyrate
in ALS. Amyotroph. Lateral Scler. 10, 99–106. doi: 10.1080/174829608023
20487
Dasgupta, B., and Milbrandt, J. (2007). Resveratrol stimulates AMP kinase activity
in neurons. Proc. Natl. Acad. Sci. U S A 104, 7217–7222. doi: 10.1073/pnas.
0610068104
de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., and van Kuilenburg,
A. B. (2003). Histone deacetylases (HDACs): characterization of the classical
HDAC family. Biochem. J. 370, 737–749. doi: 10.1042/bj20021321
Del Signore, S. J., Amante, D. J., Kim, J., Stack, E. C., Goodrich, S., Cormier, K., et al.
(2009). Combined riluzole and sodium phenylbutyrate therapy in transgenic
amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 10, 85–94. doi: 10.
1080/17482960802226148
Eijkelenboom, A., and Burgering, B. M. (2013). FOXOs: signalling integrators
for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. 14, 83–97. doi: 10.
1038/nrm3507
Figueroa-Romero, C., Hur, J., Bender, D. E., Delaney, C. E., Cataldo, M. D., Smith,
A. L., et al. (2012). Identification of epigenetically altered genes in sporadic
amyotrophic lateral sclerosis. PLoS One 7:e52672. doi: 10.1371/journal.pone.
0052672
Frew, A. J., Johnstone, R. W., and Bolden, J. E. (2009). Enhancing the apoptotic
and therapeutic effects of HDAC inhibitors. Cancer Lett. 280, 125–133. doi: 10.
1016/j.canlet.2009.02.042
Haigis, M. C., and Sinclair, D. A. (2010). Mammalian sirtuins: biological insights
and disease relevance. Annu. Rev. Pathol. 5, 253–295. doi: 10.1146/annurev.
pathol.4.110807.092250
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., et al. (2002).
HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458. doi: 10.
1038/417455a
Imai, S., Armstrong, C. M., Kaeberlein, M., and Guarente, L. (2000). Tran-
scriptional silencing and longevity protein Sir2 is an NAD-dependent histone
deacetylase. Nature 403, 795–800. doi: 10.1038/35001622
Janssen, C., Schmalbach, S., Boeselt, S., Sarlette, A., Dengler, R., and Petri, S. (2010).
Differential histone deacetylase mRNA expression patterns in amyotrophic
lateral sclerosis. J. Neuropathol. Exp. Neurol. 69, 573–581. doi: 10.1097/nen.
0b013e3181ddd404
Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., et al. (2012). Neuroprotective
role of Sirt1 in mammalian models of Huntington’s disease through activation
of multiple Sirt1 targets. Nat. Med. 18, 153–158. doi: 10.1038/nm.2558
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 243 | 5
Lazo-Gómez et al. Histone deacetylases in ALS
Kaeberlein, M., McVey, M., and Guarente, L. (1999). The SIR2/3/4 complex and
SIR2 alone promote longevity in Saccharomyces cerevisiae by two different
mechanisms. Genes Dev. 13, 2570–2580. doi: 10.1101/gad.13.19.2570
Kanai, H., Sawa, A., Chen, R. W., Leeds, P., and Chuang, D. M. (2004). Valproic
acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced
GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacoge-
nomics J. 4, 336–344. doi: 10.1038/sj.tpj.6500269
Kazantsev, A. G., and Thompson, L. M. (2008). Therapeutic application of histone
deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug
Discov. 7, 854–868. doi: 10.1038/nrd2681
Kernochan, L. E., Russo, M. L., Woodling, N. S., Huynh, T. N., Avila, A. M.,
Fischbeck, K. H., et al. (2005). The role of histone acetylation in SMN gene
expression.Hum. Mol. Genet. 14, 1171–1182. doi: 10.1093/hmg/ddi130
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T.,
et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models
for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–
3179. doi: 10.1038/sj.emboj.7601758
Kim, S. H., Shanware, N. P., Bowler, M. J., and Tibbetts, R. S. (2010). Amyotrophic
lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common
biochemical complex to co-regulate HDAC6 mRNA. J. Biol. Chem. 285, 34097–
34105. doi: 10.1074/jbc.m110.154831
Kirby, J., Halligan, E., Baptista, M. J., Allen, S., Heath, P. R., Holden, H., et al.
(2005).Mutant SOD1 alters the motor neuronal transcriptome: implications for
familial ALS. Brain 128, 1686–1706. doi: 10.1093/brain/awh503
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693–
705. doi: 10.1016/j.cell.2007.02.005
Lee, J. C., Shin, J. H., Park, B. W., Kim, G. S., Kim, J. C., Kang, K. S., et al. (2012).
Region-specific changes in the immunoreactivity of SIRT1 expression in the
central nervous system of SOD1(G93A) transgenic mice as an in vivo model
of amyotrophic lateral sclerosis. Brain Res. 1433, 20–28. doi: 10.1016/j.brainres.
2011.11.019
Li, X. (2013). SIRT1 and energy metabolism. Acta Biochim. Biophys. Sin. (Shanghai)
45, 51–60. doi: 10.1093/abbs/gms108
Liang, H.,Ward,W. F., Jang, Y. C., Bhattacharya, A., Bokov, A. F., Li, Y., et al. (2011).
PGC-1alpha protects neurons and alters disease progression in an amyotrophic
lateral sclerosis mouse model. Muscle Nerve 44, 947–956. doi: 10.1002/mus.
22217
Liu, D., Gharavi, R., Pitta, M., Gleichmann, M., and Mattson, M. P. (2009a).
Nicotinamide prevents NAD+ depletion and protects neurons against excito-
toxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger
energetically compromised neurons. Neuromolecular Med. 11, 28–42. doi: 10.
1007/s12017-009-8058-1
Liu, H., Hu, Q., D’Ercole A, J., and Ye, P. (2009b). Histone deacetylase 11 regulates
oligodendrocyte-specific gene expression and cell development in OL-1 oligo-
dendroglia cells. Glia 57, 1–12. doi: 10.1002/glia.20729
Liu, H., Hu, Q., Kaufman, A., D’Ercole, A. J., and Ye, P. (2008). Developmental
expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res. 86,
537–543. doi: 10.1002/jnr.21521
Michan, S., and Sinclair, D. (2007). Sirtuins in mammals: insights into their
biological function. Biochem. J. 404, 1–13. doi: 10.1042/bj20070140
Mojsilovic-Petrovic, J., Nedelsky, N., Boccitto, M., Mano, I., Georgiades, S. N.,
Zhou, W., et al. (2009). FOXO3a is broadly neuroprotective in vitro and in vivo
against insults implicated in motor neuron diseases. J. Neurosci. 29, 8236–8247.
doi: 10.1523/jneurosci.1805-09.2009
Monti, B., Polazzi, E., and Contestabile, A. (2009). Biochemical, molecular and
epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol.
2, 95–109. doi: 10.2174/1874-470210902010095
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky,
N. B., et al. (2007). HDAC6 rescues neurodegeneration and provides an
essential link between autophagy and the UPS. Nature 447, 859–863. doi: 10.
1038/nature05853
Petri, S., Kiaei, M., Kipiani, K., Chen, J., Calingasan, N. Y., Crow, J. P., et al.
(2006). Additive neuroprotective effects of a histone deacetylase inhibitor and
a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral
sclerosis.Neurobiol. Dis. 22, 40–49. doi: 10.1016/j.nbd.2005.09.013
Piepers, S., Veldink, J. H., de Jong, S. W., van der Tweel, I., van der Pol, W. L.,
Uijtendaal, E. V., et al. (2009). Randomized sequential trial of valproic acid in
amyotrophic lateral sclerosis. Ann. Neurol. 66, 227–234. doi: 10.1002/ana.21620
Robakis, N. K. (2003). An Alzheimer’s disease hypothesis based on transcriptional
dysregulation. Amyloid 10, 80–85. doi: 10.3109/13506120309041729
Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral
sclerosis.Nat. Rev. Neurosci. 14, 248–264. doi: 10.1038/nrn3430
Rouaux, C., Panteleeva, I., Rene, F., Gonzalez de Aguilar, J. L., Echaniz-Laguna, A.,
Dupuis, L., et al. (2007). Sodium valproate exerts neuroprotective effects in vivo
through CREB-binding protein-dependent mechanisms but does not improve
survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27, 5535–
5545. doi: 10.1523/jneurosci.1139-07.2007
Ryu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., et al. (2005).
Sodium phenylbutyrate prolongs survival and regulates expression of anti-
apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem.
93, 1087–1098. doi: 10.1111/j.1471-4159.2005.03077.x
Santa-Cruz, L. D., Ramírez-Jarquín, U. N., and Tapia, R. (2012). “Role of mito-
chondrial dysfunction in motor neuron degeneration in ALS,” in Amyotrophic
Lateral Sclerosis, ed M. H. Maurer (In Tech, Rijeka, Croatia). 197–224.
Selvi, B. R., Cassel, J. C., Kundu, T. K., and Boutillier, A. L. (2010). Tuning
acetylation levels withHAT activators: therapeutic strategy in neurodegenerative
diseases. Biochim. Biophys. Acta 1799, 840–853. doi: 10.1016/j.bbagrm.2010.08.
012
Smith, J. S., Brachmann, C. B., Celic, I., Kenna, M. A., Muhammad, S., Starai,
V. J., et al. (2000). A phylogenetically conserved NAD+-dependent protein
deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. U S A 97,
6658–6663. doi: 10.1073/pnas.97.12.6658
Song, W., Song, Y., Kincaid, B., Bossy, B., and Bossy-Wetzel, E. (2013). Mutant
SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neu-
rons: neuroprotection by SIRT3 and PGC-1alpha. Neurobiol. Dis. 51, 72–81.
doi: 10.1016/j.nbd.2012.07.004
Tang, B. L. (2010). Resveratrol is neuroprotective because it is not a direct activator
of Sirt1- A hypothesis. Brain Res. Bull. 81, 359–361. doi: 10.1016/j.brainresbull.
2009.12.007
Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007). Nucle-
ocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J.
Biol. Chem. 282, 6823–6832. doi: 10.1074/jbc.m609554200
Thau, N., Knippenberg, S., Korner, S., Rath, K. J., Dengler, R., and Petri, S.
(2012). Decreased mRNA expression of PGC-1alpha and PGC-1alpha-regulated
factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J.
Neuropathol. Exp. Neurol. 71, 1064–1074. doi: 10.1097/nen.0b013e318275df4b
Todd, P. K., Oh, S. Y., Krans, A., Pandey, U. B., Di Prospero, N. A., Min, K. T., et al.
(2010). Histone deacetylases suppress CGG repeat-induced neurodegeneration
via transcriptional silencing inmodels of fragile X tremor ataxia syndrome. PLoS
Genet. 6:e1001240. doi: 10.1371/journal.pgen.1001240
Tovar-y-Romo, L. B., Zepeda, A., and Tapia, R. (2007). Vascular endothelial growth
factor prevents paralysis and motoneuron death in a rat model of excitotoxic
spinal cord neurodegeneration. J. Neuropathol. Exp. Neurol. 66, 913–922. doi: 10.
1097/nen.0b013e3181567c16
Wang, J., Zhang, Y., Tang, L., Zhang, N., and Fan, D. (2011). Protective effects
of resveratrol through the up-regulation of SIRT1 expression in the mutant
hSOD1–G93A-bearing motor neuron-like cell culture model of amyotrophic
lateral sclerosis.Neurosci. Lett. 503, 250–255. doi: 10.1016/j.neulet.2011.08.047
Yacoubian, T. A., Cantuti-Castelvetri, I., Bouzou, B., Asteris, G., McLean, P. J.,
Hyman, B. T., et al. (2008). Transcriptional dysregulation in a transgenic model
of Parkinson disease. Neurobiol. Dis. 29, 515–528. doi: 10.1016/j.nbd.2007.11.
008
Yao, Z. G., Zhang, L., Huang, L., Zhu, H., Liu, Y., Ma, C. M., et al. (2013). Regional
and cell-type specific distribution of HDAC2 in the adult mouse brain. Brain
Struct. Funct. 218, 563–573. doi: 10.1007/s00429-012-0416-3
Yoo, Y. E., and Ko, C. P. (2011). Treatment with trichostatin A initiated after
disease onset delays disease progression and increases survival in a mouse
model of amyotrophic lateral sclerosis. Exp. Neurol. 231, 147–159. doi: 10.1016/j.
expneurol.2011.06.003
Zakhary, S. M., Ayubcha, D., Dileo, J. N., Jose, R., Leheste, J. R., Horowitz,
J. M., et al. (2010). Distribution analysis of deacetylase SIRT1 in rodent and
human nervous systems. Anat. Rec. (Hoboken) 293, 1024–1032. doi: 10.1002/ar.
21116
Zhao, W., Varghese, M., Yemul, S., Pan, Y., Cheng, A., Marano, P., et al. (2011a).
Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-
1alpha) improves motor performance and survival in a mouse model of
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 243 | 6
Lazo-Gómez et al. Histone deacetylases in ALS
amyotrophic lateral sclerosis. Mol. Neurodegener. 6:51. doi: 10.1186/1750-1326-
6-51
Zhao, Y., Wang, Y., and Zhu, W. G. (2011b). Applications of post-translational
modifications of FoxO family proteins in biological functions. J. Mol. Cell Biol.
3, 276–282. doi: 10.1093/jmcb/mjr013
Zhou, V.W., Goren, A., and Bernstein, B. E. (2011). Charting histone modifications
and the functional organization of mammalian genomes.Nat. Rev. Genet. 12, 7–
18. doi: 10.1038/nrg2905
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 06 August 2013; paper pending published: 11 October 2013; accepted: 16
November 2013; published online: 05 December 2013.
Citation: Lazo-Gómez R, Ramírez-Jarquín UN, Tovar-y-Romo LB and Tapia R
(2013) Histone deacetylases and their role in motor neuron degeneration. Front. Cell.
Neurosci. 7:243. doi: 10.3389/fncel.2013.00243
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2013 Lazo-Gómez, Ramírez-Jarquín, Tovar-y-Romo and Tapia. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 243 | 7
